Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy, in patients with refractory DLBCL. Patients received low-dose conditionin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Ther
Auteurs principaux: Locke, Frederick L., Neelapu, Sattva S., Bartlett, Nancy L., Siddiqi, Tanya, Chavez, Julio C., Hosing, Chitra M., Ghobadi, Armin, Budde, Lihua E., Bot, Adrian, Rossi, John M., Jiang, Yizhou, Xue, Allen X., Elias, Meg, Aycock, Jeff, Wiezorek, Jeff, Go, William Y.
Format: Artigo
Langue:Inglês
Publié: American Society of Gene & Cell Therapy 2017
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363293/
https://ncbi.nlm.nih.gov/pubmed/28129122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2016.10.020
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires